Study of Two Doses of ALIMTA (Pemetrexed) as First Line Chemotherapy for Advanced Breast Cancer

CompletadoFase 2ClinicalTrials.gov

ID: NCT00065533Tipo: INTERVENTIONALInicio: 1 de may de 2003Fin estimado: 1 de jun de 2005

Traducción no disponible, mostrando original

Resumen

The purposes of this study are to determine the safety of pemetrexed and any side effects that might be associated with it, whether pemetrexed can help patients with breast cancer and how much pemetrexed should be given to patients.

Elegibilidad

Edad mínima: 18 YearsSexo: ALL

Criterios de inclusión

Be at least 18 years of old.
Have been diagnosed with breast cancer
At least one year disease-free interval after initial treatment.
Have pre-study laboratory tests that are within the requirements of this study.
Be able to visit the doctor's office weekly during the treatment period.

Criterios de exclusión

To be pregnant or breastfeeding.
To be currently taking aspirin or aspirin- like medicine and unable to stop for a few days during each cycle of therapy.
To have received prior chemotherapy for the treatment of metastatic cancer. Patients may have received prior hormonal treatment.
To have another illness that your doctor thinks would make you unable to participate.
To be unable or not willing to take folic acid and vitamin B12.

Intervenciones

drug

pemetrexed

Ubicaciones

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hrs, EST), or speak with your personal physician.

Buenos Aires, Argentina

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hrs, EST), or speak with your personal physician.

Capitol Federal, Argentina

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hrs, EST), or speak with your personal physician.

S.M. de Tucuman, Argentina

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hrs, EST), or speak with your personal physician.

San Miguel de Tucumán, Argentina

Patrocinadores

PrincipalEli Lilly and Company

Aviso: La información de este ensayo proviene de fuentes públicas y tiene carácter exclusivamente informativo. No constituye asesoramiento médico, regulatorio ni de ningún otro tipo. Las traducciones son automatizadas y no poseen validez oficial. Consultá siempre con un profesional de la salud. Ver Términos de Uso.

Study of Two Doses of ALIMTA (Pemetrexed) as First Line C... | EligiMed